Evaluation of Guidelines on Diabetes Medication
Authors: Keith Brown, Robin Harbour, John Petrie
Journal: Annals of Internal Medicine (2012)

Letters15 May 2012Evaluation of Guidelines on Diabetes MedicationKeith Brown, MD, Robin Harbour, PhD, and John Petrie, MD, PhDKeith Brown, MDFrom University of Glasgow, Glasgow G12 8TA, Scotland.Search for more papers by this author, Robin Harbour, PhDFrom University of Glasgow, Glasgow G12 8TA, Scotland.Search for more papers by this author, and John Petrie, MD, PhDFrom University of Glasgow, Glasgow G12 8TA, Scotland.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-156-10-201205150-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We were interested to read Bennett and colleagues' systematic review (1) on the evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus. However, we were surprised by the omission of the 2010 update of the Scottish Intercollegiate Guidelines Network (SIGN) guideline on the management of diabetes (2). This guideline covers all aspects of diabetes, with a specific chapter addressing medication for type 2 diabetes, therefore meeting the review's main inclusion criteria.In relation to Bennett and colleagues' other inclusion criteria, SIGN guidelines provide evidence-based guidance for the National Health Service in Scotland, a constituent ...References1. Bennett WL, Odelola OA, Wilson LM, Bolen S, Selvaraj S, Robinson KA, et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann Intern Med. 2012;156:27-36. [PMID: 22213492] LinkGoogle Scholar2. Scottish Intercollegiate Guidelines Network. Management of Diabetes: A National Clinical Guideline. Guideline no. 116. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network; 2010. Accessed 10 April 2012 at www.sign.ac.uk/guidelines/fulltext/116/index.html. Google Scholar Author, Article, and Disclosure InformationAuthors: Keith Brown, MD; Robin Harbour, PhD; John Petrie, MD, PhDAffiliations: From University of Glasgow, Glasgow G12 8TA, Scotland.Disclosures: Dr. Petrie has provided consultancy or served on trial committees for pharmaceutical companies manufacturing products for the treatment of diabetes, including Bristol-Myers Squibb Pharma, Daaichi Sankyo, GlaxoSmithKline, Novo Nordisk, Pfizer, Roche, and Takeda. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEvaluation of Guideline Recommendations on Oral Medications for Type 2 Diabetes Mellitus Wendy L. Bennett , Olaide A. Odelola , Lisa M. Wilson , Shari Bolen , Saranya Selvaraj , Karen A. Robinson , Eric B. Bass , and Milo A. Puhan Evaluation of Guidelines on Diabetes Medication Andrea Giaccari , Carlo B. Giorda , Gabriele Riccardi , Alberto De Micheli , Graziella Bruno , Luca Monge , and Simona Frontoni Evaluation of Guidelines on Diabetes Medication Wendy L. Bennett , Olaide A. Odelola , and Lisa M. Wilson Metrics Cited byType 2 diabetes guidelines: keeping Scotland on the map 15 May 2012Volume 156, Issue 10Page: 752KeywordsConflicts of interestHealth careHealth care policyMedical servicesPublic policySystematic reviewsTreatment guidelinesType 2 diabetes ePublished: 15 May 2012 Issue Published: 15 May 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...